Chemotherapy Induced Neutropenia – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Chemotherapy Induced Neutropenia – Pipeline Review, H2 2018’, provides an overview of the Chemotherapy Induced Neutropenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia

– The report reviews pipeline therapeutics for Chemotherapy Induced Neutropenia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Chemotherapy Induced Neutropenia therapeutics and enlists all their major and minor projects

– The report assesses Chemotherapy Induced Neutropenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Neutropenia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

BeyondSpring Pharmaceuticals Inc

Biocon Ltd

Bolder Biotechnology Inc

Cellerant Therapeutics Inc

Chong Kun Dang Pharmaceutical Corp

Cinfa Biotech SL

Dr. Reddy's Laboratories Ltd

Gene Techno Science Co Ltd

Generon (Shanghai) Corp Ltd

GlycoMimetics Inc

Hanmi Pharmaceuticals Co Ltd

Lupin Ltd

Mycenax Biotech Inc

Nohla Therapeutics Inc

Pangen Biotech Inc.

Pfizer Inc

Profarma

Prolong Pharmaceuticals LLC

Richter Gedeon Nyrt

Sandoz International GmbH

USV Pvt Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chemotherapy Induced Neutropenia Overview

Chemotherapy Induced Neutropenia Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Chemotherapy Induced Neutropenia Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chemotherapy Induced Neutropenia Companies Involved in Therapeutics Development

BeyondSpring Pharmaceuticals Inc

Biocon Ltd

Bolder Biotechnology Inc

Cellerant Therapeutics Inc

Chong Kun Dang Pharmaceutical Corp

Cinfa Biotech SL

Dr. Reddy's Laboratories Ltd

Gene Techno Science Co Ltd

Generon (Shanghai) Corp Ltd

GlycoMimetics Inc

Hanmi Pharmaceuticals Co Ltd

Lupin Ltd

Mycenax Biotech Inc

Nohla Therapeutics Inc

Pangen Biotech Inc.

Pfizer Inc

Profarma

Prolong Pharmaceuticals LLC

Richter Gedeon Nyrt

Sandoz International GmbH

USV Pvt Ltd

Chemotherapy Induced Neutropenia Drug Profiles

BBT-007 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BBT-015 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Chemotherapy Induced Neutropenia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dilanubicel Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EC-18 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eflapegrastim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

F-627 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GW-003 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GXG-3 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lenograstim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Myelo-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plinabulin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

romyelocel-L Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SFR-9314 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

uproleselan sodium Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WBI-2100 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YPEG-Filgrastim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chemotherapy Induced Neutropenia Dormant Projects

Chemotherapy Induced Neutropenia Discontinued Products

Chemotherapy Induced Neutropenia Product Development Milestones

Featured News & Press Releases

Jun 25, 2018: Spectrum Pharmaceuticals to Host Conference Call Highlighting ROLONTIS (eflapegrastim) Phase 3 ADVANCE Study Data Presented at Multinational Association of Supportive Care in Cancer (MASCC)

May 17, 2018: BeyondSpring to Present Positive Data From Prospective Phase 2 Trial Comparing Plinabulin to Neulasta for the Prevention of Chemotherapy-Induced Neutropenia at 2018 ASCO Annual Meeting

May 16, 2018: Spectrum Pharmaceuticals Announces Detailed Results from Phase 3 Study of ROLONTIS (eflapegrastim) Published in an ASCO Abstract

Apr 27, 2018: Bolder BioTechnology Announces Positive Results from Phase 1 Clinical Trial of BBT-015, a Long-Acting G-CSF Analog, in Healthy Volunteers

Apr 24, 2018: Enzychem Lifesciences Fast Track Designation for chemo-radiation induced oral mucositis had been granted by the FDA

Apr 17, 2018: BeyondSpring Presents Lead Asset’s Mechanism Data for Prevention of Chemotherapy-Induced Neutropenia

Mar 19, 2018: BeyondSpring Announces Initiation of Phase 3 Clinical Development for Plinabulin for Prevention of Chemotherapy-Induced Neutropenia

Feb 05, 2018: Spectrum Pharmaceuticals Announces ROLONTIS (eflapegrastim) Met the Primary Endpoint in the Phase 3 ADVANCE Study

Feb 05, 2018: BeyondSpring Summarizes Key Messages from KOL Call regarding Lead Asset Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia

Jan 26, 2018: BeyondSpring Presents Promising Data for Lead Asset Plinabulin at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Jan 25, 2018: Generon Successfully Concludes First Phase III Clinical Trial of F-627 for Chemotherapy-induced Neutropenia

Jan 17, 2018: BeyondSpring to Present Data from Phase 2 Portion of Study 105 Phase 2/3 Trial with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Dec 14, 2017: Cinfa Biotech begins US partnering and prepares US development for B12019, a proposed biosimilar to Neulasta (pegfilgrastim)

Dec 14, 2017: BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia

Dec 04, 2017: BeyondSpring’s Lead Asset, Plinabulin, Recognized as 2017 National Science and Technology Major Project in China

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Chemotherapy Induced Neutropenia Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2018

Chemotherapy Induced Neutropenia Pipeline by Biocon Ltd, H2 2018

Chemotherapy Induced Neutropenia Pipeline by Bolder Biotechnology Inc, H2 2018

Chemotherapy Induced Neutropenia Pipeline by Cellerant Therapeutics Inc, H2 2018

Chemotherapy Induced Neutropenia Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2018

Chemotherapy Induced Neutropenia Pipeline by Cinfa Biotech SL, H2 2018

Chemotherapy Induced Neutropenia Pipeline by Dr. Reddy's Laboratories Ltd, H2 2018

Chemotherapy Induced Neutropenia Pipeline by Gene Techno Science Co Ltd, H2 2018

Chemotherapy Induced Neutropenia Pipeline by Generon (Shanghai) Corp Ltd, H2 2018

Chemotherapy Induced Neutropenia Pipeline by GlycoMimetics Inc, H2 2018

Chemotherapy Induced Neutropenia Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2018

Chemotherapy Induced Neutropenia Pipeline by Lupin Ltd, H2 2018

Chemotherapy Induced Neutropenia Pipeline by Mycenax Biotech Inc, H2 2018

Chemotherapy Induced Neutropenia Pipeline by Nohla Therapeutics Inc, H2 2018

Chemotherapy Induced Neutropenia Pipeline by Pangen Biotech Inc., H2 2018

Chemotherapy Induced Neutropenia Pipeline by Pfizer Inc, H2 2018

Chemotherapy Induced Neutropenia Pipeline by Profarma, H2 2018

Chemotherapy Induced Neutropenia Pipeline by Prolong Pharmaceuticals LLC, H2 2018

Chemotherapy Induced Neutropenia Pipeline by Richter Gedeon Nyrt, H2 2018

Chemotherapy Induced Neutropenia Pipeline by Sandoz International GmbH, H2 2018

Chemotherapy Induced Neutropenia Pipeline by USV Pvt Ltd, H2 2018

Chemotherapy Induced Neutropenia Dormant Projects, H2 2018

Chemotherapy Induced Neutropenia Dormant Projects, H2 2018 (Contd..1), H2 2018

Chemotherapy Induced Neutropenia Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared